Lyophilised Oxalobacter formigenes - OxThera AB

Drug Profile

Lyophilised Oxalobacter formigenes - OxThera AB

Alternative Names: IxOC 3; Lyophylised Oxalobacter formigenes; OC 3; OC5; Oxabact; Oxalobacter formigenes product - OxThera AB

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ixion Biotechnology
  • Developer OxThera
  • Class Bacteria; Probiotics
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome; Primary hyperoxaluria
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Primary hyperoxaluria
  • No development reported Short bowel syndrome

Most Recent Events

  • 08 Nov 2017 oxThera has patent protection for Oxalobacter formigenes in Europe, Canada, China, Hong-Kong, India and Japan
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Short-bowel-syndrome in Sweden (PO, Capsule)
  • 07 Apr 2017 OxThera plans a phase III trial for Primary hyperoxaluria (NCT03116685)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top